Study guide

15.3 Medicare ESRD Payment, ESRD Networks, EQRS & the Survey Measures Assessment Tool

Board Certified Specialist in Renal Nutrition CSR

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Kidney Disease Foundations

1.1 CDR CSR Exam Structure, Eligibility, Logistics & the 2023 Content Outline 1.2 Renal Anatomy, Physiology & Glomerular Hemodynamics 1.3 CKD Etiology, KDIGO Staging & Progression Risk

2 Chapter 2: Domain 1 — Anthropometric & Body Composition Assessment

2.1 Dry Weight Determination, Fluid Assessment & Interdialytic Weight Gain 2.2 Anthropometric Measurement Standards (Knee Height, Skinfolds, Frame Size) 2.3 Body Composition Analysis: BIA, BIS, DXA & Handgrip Dynamometry

3 Chapter 3: Domain 1 — Nutrition-Focused Physical Findings & PEW Assessment Tools

3.1 Protein-Energy Wasting (PEW) Diagnostic Criteria & Pathophysiology 3.2 Subjective Global Assessment (7-Point SGA) in Dialysis 3.3 Malnutrition Inflammation Score (MIS) & Scoring Protocols 3.4 Nutrition-Focused Physical Exam (NFPE) for Muscle & Fat Loss

4 Chapter 4: Domain 1 — Diet, Medical, Medication & Psychosocial History

4.1 Dietary Intake Assessment & Food Frequency Methods in CKD 4.2 Medical & Medication History: Drug–Nutrient Interactions and Supplements 4.3 Psychosocial, Social & Functional History in Renal Nutrition Assessment

5 Chapter 5: Domain 1 — Medical Tests & Procedures by Treatment Modality

5.1 Hemodialysis Clinical Assessment & Vascular Access Considerations 5.2 Peritoneal Dialysis & Peritoneal Glucose Absorption Assessment 5.3 AKI, CRRT & Pediatric Renal Disease Assessment

6 Chapter 6: Domain 1 — Nutrition Diagnosis: Terminology, Etiology & Reasoning

6.1 Standardized Nutrition Diagnostic Terminology (NCP) in Nephrology 6.2 Etiology & Root-Cause Analysis for Renal Nutrition Problems 6.3 Diagnostic Reasoning for Fluid, Mineral & Protein Imbalances

7 Chapter 7: Domain 1 — Nutrition Diagnosis in Complex Patients

7.1 Formulating Valid PES Statements in Complex Dialysis Patients 7.2 Differentiating PEW, Sarcopenia & Cachexia in CKD 7.3 Diagnostic Prioritization across Cardiorenal & Diabetic Nephropathy

8 Chapter 8: Domain 2 — Food & Nutrient Delivery: Protein & Energy

8.1 KDOQI 2020 Protein Targets: Non-Dialysis CKD (LPD vs. VLPD) 8.2 Protein Prescriptions for Hemodialysis and Peritoneal Dialysis 8.3 Energy Requirements, Carbohydrates & Plant-Dominant Diets (PLADO)

9 Chapter 9: Domain 2 — Electrolytes, Fluid, Acid–Base & Micronutrients

9.1 Potassium Management: Dietary Restriction, Leaching & K-Binders 9.2 Sodium & Fluid Prescriptions across Dialysis Modalities 9.3 Acid-Base Homeostasis & Bicarbonate Replacement Therapy 9.4 Micronutrient, Trace Mineral & Vitamin Supplementation in ESRD

10 Chapter 10: Domain 2 — Medications & Specialized Nutrition Support

10.1 CKD-MBD Pharmacology: Phosphorus Binders, Vitamin D & Calcimimetics 10.2 Anemia Management: Iron Homeostasis, IV Iron Protocols & ESAs 10.3 Enteral, IDPN & Intraperitoneal Amino Acid Nutrition Support

11 Chapter 11: Domain 2 — Treatments Across the Continuum: Transplant & Comorbidities

11.1 Kidney Transplant I: Candidacy, Living Donors & the Early Post-Transplant Period 11.2 Kidney Transplant II: Long-Term Care, Immunosuppressant Side Effects & Graft Protection 11.3 Diabetes Management Across CKD Stages: Glycemic Targets, Medications & MNT 11.4 GI & Cardiovascular Comorbidities: Gastroparesis, Constipation, Liver Disease, Lipids & Blood Pressure

12 Chapter 12: Domain 2 — Monitoring & Evaluation: Labs, Fluid & Nutrition Trends

12.1 Renal Laboratory Surveillance: Frequency, Target Ranges & Trending 12.2 Monitoring Fluid Balance, Blood Pressure & Cardiovascular Risk 12.3 Longitudinal Assessment of Nutritional Status & Weight Trajectories

13 Chapter 13: Domain 2 — Monitoring Dialysis Adequacy & Kinetics

13.1 Hemodialysis Adequacy: Urea Kinetic Modeling, spKt/V & URR 13.2 Peritoneal Dialysis Adequacy & Peritoneal Equilibration Test (PET) 13.3 Normalized Protein Catabolic Rate (nPCR / nPNA) Interpretation 13.4 Troubleshooting Inadequate Dialysis vs. Dietary Non-Adherence

14 Chapter 14: Domain 2 — Care Coordination, Communication & Education

14.1 Interdisciplinary Team Care, Patient Education & Counseling Ethics 14.2 Individualized & Group Education: Medicare MNT and KDE Benefits, Caregivers & Curricula 14.3 Interfacility Coordination of Care: Hospital Handoffs, Transfers, Transplant Centers & Modality Changes 14.4 Psychosocial Support & Resources: Food Assistance, Financial Programs, Rehabilitation & Peer Support

15 Chapter 15: Domain 3 — Regulations & Quality Management

15.1 CMS Conditions for Coverage: IDT, Dietitian Qualifications, Assessment & Plan-of-Care Timelines 15.2 QAPI Programs, PDSA Cycles & the ESRD Quality Incentive Program 15.3 Medicare ESRD Payment, ESRD Networks, EQRS & the Survey Measures Assessment Tool

16 Chapter 16: Domain 3 — Evidence-Based Practice: Guidelines, Research & Protocols

16.1 The KDOQI 2020 Nutrition in CKD Guideline (NKF–Academy EAL): Grades & Key Statements 16.2 KDIGO & Companion Guidelines: CKD 2024, CKD-MBD, Anemia 2026, Diabetes, BP, Lipids & AKI 16.3 Appraising Current Research: Study Designs, Bias, Statistics & Landmark Renal Trials 16.4 Clinical Protocols & Algorithms: Dietitian-Managed MBD, Anemia, Potassium & Nutrition-Support Pathways

15.3 Medicare ESRD Payment, ESRD Networks, EQRS & the Survey Measures Assessment Tool

Key Takeaways Explain This Topic AI

The ESRD PPS pays one bundled per-treatment rate (base rate $281.71 for CY 2026) that covers dialysis-related drugs, labs and supplies; new drugs enter through a transitional drug add-on payment adjustment (TDAPA).

Oral phosphate binders (calcium acetate, sevelamer, lanthanum, sucroferric oxyhydroxide, ferric citrate) have been paid under the ESRD PPS with the TDAPA since January 1, 2025, for at least 2 years.

The CMS Measures Assessment Tool lists albumin of 4.0 g/dL or higher by bromocresol green (or the lab's normal range for bromocresol purple), measured monthly with body weight.

The survey tool also lists avoiding an ultrafiltration rate of 13 mL/kg/hr or higher, spKt/V of at least 1.2 (or URR at least 65%), and at least 3 hours per treatment when residual kidney function is below 2 mL/min.

Dialysis facilities must cooperate with their ESRD Network (42 CFR 494.180(i)); Networks handle grievances, regional quality projects and notices of involuntary discharge.

Last updated: September 2026

Why this belongs in Domain 3

The CSR outline's regulatory topic goes beyond the Conditions for Coverage. The CDR reference list includes the ESRD Quality Initiative , the Measures Assessment Tool (MAT) used by surveyors, and State Operations Manual Appendix X for transplant programs. Knowing how dialysis is paid, how data are reported and how surveyors judge outcomes explains many day-to-day rules, from who supplies phosphate binders to why albumin is drawn every month.

The ESRD prospective payment system (PPS)

Since 2011, Medicare has paid dialysis facilities a single bundled payment per treatment . The bundle covers the dialysis treatment plus renal dialysis services: labs, supplies and drugs such as ESAs, IV iron, IV vitamin D analogs and, since 2021, calcimimetics. Key features:

Base rate: set each year by rulemaking. It is $281.71 per treatment for CY 2026 .

Adjustments: patient case-mix (age, body size, onset of dialysis, some comorbidities), facility low-volume and rural adjustments, wage index, and an outlier payment for unusually high-cost patients.

Home dialysis training add-on , paid per training treatment.

TDAPA (transitional drug add-on payment adjustment): new renal dialysis drugs are paid on top of the base rate for a set period, usually at least 2 years, before CMS folds their cost into the base rate. Calcimimetics followed this path.

Oral-only drugs: since January 1, 2025 , oral phosphate binders (sevelamer carbonate and hydrochloride, sucroferric oxyhydroxide, lanthanum carbonate, ferric citrate and calcium acetate) are paid through the TDAPA under the ESRD PPS instead of Part D. The dialysis facility therefore supplies them. Vadadustat, an oral HIF-PH inhibitor, received TDAPA for 2025–2026.

AKI dialysis: Medicare pays ESRD facilities for dialysis for patients with acute kidney injury at a rate tied to the ESRD PPS base rate.

What this means for dietitians. Because the bundle includes these drugs, binder and anemia protocols affect facility costs, and binder supply now runs through the facility. Renal MNT cannot be billed separately for patients on maintenance dialysis (42 CFR 410.132(b)(1)); dietitian services are part of the dialysis payment.

ESRD Networks

CMS contracts with ESRD Network Organizations , one for each of 18 geographic areas, to improve quality and support patients. Networks:

run regional quality-improvement projects, for example on home dialysis, transplant waitlisting, vascular access and infection prevention;

take patient grievances and help with difficult transfers and involuntary discharges; a facility must give the patient and the Network 30 days' notice of a planned involuntary discharge;

collect and validate data, and help with emergency and disaster preparedness.

Under 42 CFR 494.180(i), each facility must cooperate with its Network , act on its recommendations and pursue Network goals. The MAT tells facilities to use their Network's goals as targets for aggregate patient outcomes.

Data reporting: EQRS and CMS forms

Facilities must submit data electronically as CMS specifies (§494.180(h)). The ESRD Quality Reporting System (EQRS) , which replaced CROWNWeb, holds patient events, monthly clinical values (for example, calcium, hemoglobin, Kt/V and albumin) and QIP reporting data. Key forms:

CMS-2728 (ESRD Medical Evidence Report): completed when a patient starts dialysis or gets a transplant. It records entitlement data, lab values at the start of treatment and pre-dialysis care, including prior care by a kidney dietitian.

CMS-2746 (ESRD Death Notification).

Nutrition values entered each month feed QAPI dashboards, the Dialysis Facility Reports and public reporting.

The survey process and the Measures Assessment Tool

State survey agencies inspect dialysis facilities for CMS using the ESRD Core Survey process, standardized worksheets and V-tags that map each CfC requirement. The Measures Assessment Tool (MAT, version 2.5) summarizes the clinical values surveyors use to judge whether the team recognized and acted on out-of-range outcomes. Surveyors cite a facility for failing to act , not for an individual out-of-range value.

Area (CfC tag) MAT value or expectation

Volume status (V543) Euvolemia; pre-dialysis BP below 140/90 and post-dialysis below 130/80 (adults); avoid UFR of 13 mL/kg/hr or higher (NQF #2701)

HD adequacy (V544) spKt/V of at least 1.2 (or URR of at least 65%) for thrice-weekly HD; at least 3 hours per treatment when residual kidney function is below 2 mL/min ; stdKt/V of at least 2.0 per week for other schedules; monitor monthly

PD adequacy (V544) Weekly Kt/Vurea of at least 1.7 in adults (1.8 in children); measure in the first month and every 4 months

Nutrition (V545) Albumin at least 4.0 g/dL by BCG (preferred); if BCP, the lab's normal range ; albumin and body weight monthly; other indicators: % usual weight, % standard weight, BMI, estimated body fat

Pediatric nutrition (V545) Monthly length or height, weight, BMI-for-age and head circumference (under age 3); nPCR in adolescents on HD

Mineral metabolism (V546) Uncorrected calcium in the lab's normal range or below 10.2 mg/dL (3-month rolling average); phosphorus 3.5–5.5 mg/dL; calcium and phosphorus monthly; intact PTH every 3 months

Anemia on ESA (V547) Start ESAs below 10 g/dL; interrupt or reduce the dose near or above 11 g/dL (FDA 2011 labeling)

Iron (V549) TSAT above 20%; ferritin above 200 ng/mL (HD) or 100 ng/mL (PD) and below 500 ng/mL, or evaluate

Water and dialysate (V178–V196) Total chlorine at most 0.1 mg/L; bacteria action level 50 CFU/mL and maximum 200 CFU/mL; endotoxin action level 1 EU/mL and maximum 2 EU/mL

Vascular access (QAPI) Catheters in place more than 90 days below 10%; fistulas at least 65–66%

Some MAT values come from older guidelines (for example, KDOQI 2006 iron targets and KDIGO 2009 phosphorus). Current guidelines may differ, such as the KDIGO 2026 anemia guidance. On the exam, answer survey questions with the survey tool and clinical questions with the current guideline.

Public reporting

Dialysis Facility Care Compare shows star ratings from 1 to 5, quality measure results and patient-experience data. ESRD QIP scores are also public, and facilities post their QIP performance certificates. These reports make nutrition-related outcomes, such as hospitalization and transfusion ratios, visible to patients.

Transplant program requirements

Transplant programs have their own Medicare conditions of participation ( 42 CFR 482.72–482.104 ), which surveyors apply using SOM Appendix X . Relevant to dietitians:

§482.94(e) Nutritional services: nutrition assessment and diet counseling by a qualified dietitian (meeting state requirements and registered with CDR) must be available to all transplant patients and living donors .

§482.94(a): each transplant patient and living donor must be under a multidisciplinary team coordinated by a physician.

§482.94(c): the program must tell the patient and the dialysis facility about listing decisions, and must notify them within 10 days of removing a patient from the waiting list for reasons other than death or transplant.